The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations.

Rachel GoldsteinNatalie RabkinNoa BuchmanAviya R JacobsKhaled SandoukaBruria RaccahTamar Fisher NegevIlan MatokMeir BialerMordechai Muszkat

Published in: CNS drugs (2024)

. Therefore, prospective controlled studies are required to examine the possible non-pharmacokinetic mechanism of the effect of the LEV-apixaban or LEV-rivaroxaban combination on patients' outcomes.

Keyphrases

venous thromboembolism
atrial fibrillation
end stage renal disease
pulmonary embolism
newly diagnosed
chronic kidney disease
metabolic syndrome
skeletal muscle
weight loss